Related Experiment Videos
Familial prostate cancer: a different disease?
P A Kupelian1, E A Klein, J S Witte
1Department of Radiation Oncology, Cleveland Clinic Foundation, Case Western Reserve University, Ohio 44195, USA.
The Journal of Urology
|November 20, 1997
Summary
Patients with familial prostate cancer show a higher risk of biochemical failure after radical prostatectomy. This increased risk, particularly for distant relapse, suggests familial prostate cancer may be more aggressive.
Area of Science:
- Oncology
- Urology
- Genetics
Background:
- Familial prostate cancer (FPC) is a significant subset of prostate cancer.
- Understanding outcomes in FPC compared to sporadic prostate cancer (SPC) is crucial for treatment stratification.
Purpose of the Study:
- To compare treatment outcomes after radical prostatectomy in patients with FPC versus SPC.
- To identify factors influencing biochemical relapse-free survival, local failure, and distant metastases.
Main Methods:
- Retrospective analysis of 529 patients undergoing radical prostatectomy (1987-1996).
- Patients categorized based on a positive family history of prostate cancer in a first-degree relative.
- Proportional hazards models used to assess the impact of family history and confounding variables on outcomes.
Main Results:
- 12% of patients had a positive family history; younger age (<65) was associated with FPC.
- 5-year biochemical relapse-free survival was significantly lower in FPC (46%) vs. SPC (66%) (p=0.001).
- Positive family history was an independent predictor of biochemical failure and distant relapse, independent of other clinical and pathological factors.
Conclusions:
- Familial prostate cancer is associated with a higher likelihood of biochemical failure post-radical prostatectomy.
- The increased failure rates in FPC appear driven by higher distant relapse rates.
- Findings suggest FPC may possess a more aggressive biological profile than SPC.